Brief report · 30 Jun 2026
Conference abstractPublished 2 Oct 2017
Designed peptidomimetics disrupt protein-protein interactions mediating amyloid protein aggregation
UniversitÃ?© Paris Saclay, France
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Amyloid fibrils are self-assembled insoluble aggregates that constitute the hallmark of more than 20 serious human amyloidosis diseases, such as AlzheimerâÂ?Â?s disease (AD) and type II diabetes. Current drugs have failed to slow the progression of AD, which affects more than 35 million people worldwide. How drug candidates that reduce fibril formation act on the most neurotoxic oligomeric forms of amyloid peptide AÃ?²1-42 is far from being established. We report herein the capacity of two new classes of peptidomimetics to inhibit both AÃ?²1-42 early oligomerization and fibrillization: 1- sugar-based peptidomimetic analogs having physicochemical properties for drug-likeness[1]; 2- Ã?²-hairpin mimics[2]. A wide range of bioand physico-chemical techniques, such as Thioflavin-T fluorescence spectroscopy, transmission electronic microscopy, a new developped capillary electrophoresis method[3], electrospray differential mobility analysis[4], nuclear magnetic resonance, and surface plasmon resonance, was used in order to identify the molecular mechanisms by which these new series of molecules can delay the aggregation of AÃ?²1-42. This is the first example of small molecules that preserves the non toxic monomeric species of AÃ?²1-42. Some compounds suppress totally the toxicity of AÃ?²1-42 towards SH-SY5Y human neuroblastoma cells, even at sub-stoichiometric concentrations. This protective effect is much more significant than that observed with molecules that have undergone clinical trials which reduce AÃ?²1-42 toxicity only at stoichiometric or higher concentrations. Preliminary results on the inhibition of IAPP aggregation involved in type II diabetes will be also presented. [1] a) B. Dorgeret, L. KhemtÃ?©mourian, I. Correia, J-L Soulier, O. Lequin, S. Ongeri Eur. J. Med. Chem. 2011, 46, 5959. (b) J. Kaffy, D. Brinet, J-L Soulier, L. KhemtÃ?©mourian, O. Lequin, M. Taverna, B. Crousse, S. Ongeri, Eur. J. Med. Chem. 2014, 86, 752; c) J. Kaffy, D. Brinet, J-L Soulier, I. Correia, N. Tonali, K. F. Fera, Y. Iacone, A. R. F. Hoffmann, L. Khemtemourian, B. Crousse, M. Taylor, D. Allsop, M. Taverna, O. Lequin, S. Ongeri, J. Med. Chem. 2016, 59, 2025. [2] a) S. Pellegrino, N. Tonali, E. Erba, J. Kaffy, M. Taverna, A. Contini, M. Taylor, D. Allsop, M. L. Gelmi, S. Ongeri Chemical Science, 2017, 8, 1295; b), L. Vahdati, J. Kaffy; D. Brinet; G. Bernadat, I. Correia, S. Panzeri, R. Fanelli, O. Lequin, M. Taverna, S. Ongeri, U. Piarulli. Eur. J. Org. Chem. 2017, DOI: 10.1002/ejoc.201700010.[3] D. Brinet, J. Kaffy, F. Oukacine, S. Glumm, S. Ongeri, M. Taverna Electrophoresis 2014, 35, 3302. [4] D. Brinet, F. Gaie-Levrel, V. Delatour, J. Kaffy, S. Ongeri, M. Taverna Talanta, 2017, 165, 84-91.
Subjects
ChemistryPharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Medicinal Chemistry.
Commentary · 29 Dec 2025
Accelerating Drug Discovery: Molecular Docking and Virtual Screening
Opinion · 29 Dec 2025
Pharmacophore Modeling: A Cornerstone of Drug Discovery
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal Chemistry
- SubjectChemistry
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Sandrine Ongeri”

